Judith Lind
Krems An Der Donau, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism.
Journal: Molecular oncology
Published: February 24, 2025
Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation.
Journal: Journal for immunotherapy of cancer
Published: April 19, 2024
Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity.
Journal: Blood cancer journal
Published: April 13, 2024
On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future.
Journal: Expert opinion on pharmacotherapy
Published: July 13, 2022
The nature inspired peptide [T20K]-kalata B1 induces anti-tumor effects in anaplastic large cell lymphoma.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: May 19, 2022
Publisher Correction: JunB is a key regulator of multiple myeloma bone marrow angiogenesis.
Journal: Leukemia
Published: September 07, 2021
JunB is a key regulator of multiple myeloma bone marrow angiogenesis.
Journal: Leukemia
Published: December 14, 2020
Emerging protein kinase inhibitors for the treatment of multiple myeloma.
Journal: Expert opinion on emerging drugs
Published: July 23, 2019
Showing 1-9 of 9
Last Updated: 09/26/2026